---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-036114"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2022-03-21T23:59:59+00:00"
generated_at: "2026-06-26T21:22:23.417281+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q4/FY2021 revenue up 48%/62%; guides FY2022 $40-45M; prelim Q1 2022 ~$8M

## Summary
- Q4 2021 revenue $8.4M (+48% YoY); FY2021 revenue $29.5M (+62% YoY).
- Q4 net loss $8.6M vs $7.8M; FY net loss $33.3M vs $28.8M.
- Gross margin improved to 68% in Q4; full-year 64%.
- Cash $43.9M at Dec 31, 2021.
- FY2022 revenue guidance $40-$45M; preliminary Q1 2022 revenue ~$8.0M.

## SEC filing metadata
- accession: 0001104659-22-036114
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2022-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465922036114/0001104659-22-036114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465922036114/tm229728d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-036114
- JSON: https://secwatch.observer/filing/0001104659-22-036114.json
- Plain text: https://secwatch.observer/filing/0001104659-22-036114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.